Porth's Essentials of Pathophysiology, 4e - page 1094

C h a p t e r 4 2 Structure and Function of the Skeletal System 1077
Rogers A, Eastell R. Review: circulating osteoprotegerin and
receptor activator for nuclear factor κB ligand: clinical utility in
metabolic bone disease assessment. J Clin Endocrinol Metab.
2005;90:6323–6331.
Rosenberg A. Bones, joints, and soft tissue tumors. In: Kumar V,
Abbas AK, Fausto N, et al., eds. Robbins and Cotran Pathologic
Basis of Disease. 8th ed. Philadelphia, PA: Elsevier Saunders;
2010:1205–1210.
Ross MH, Pawlina W. Histology. 6th ed. Philadelphia, PA: Wolters
Kluwer Health/Lippincott Williams & Wilkins; 2011:218–232.
Seeman E, Delmas PD. Bone quality—The material and
structural basis of bone strength and fragility. N Engl J Med.
2006;344(21):2250–2261.
Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of
nuclear factor-κB (Rank)/Rank ligand/osteoprotegerin: clinical
implications. J Clin Endocrinol Metab. 2007;92(12):4514–4521.
Xiong J, O’Brien CA. Osteocyte RANKL: new insights
into the control of bone remodeling. J Bone Miner Res.
2012;29(3):499–505.
Porth Essentials Resources
Explore these additional resources to enhance learning
for this chapter:
• NCLEX-Style Questions and Other Resources
on , http://thePoint.lww.com/PorthEssentials4e
• Study Guide for Essentials of Pathophysiology
• Adaptive Learning | Powered by PrepU,http://thepoint.lww.com/
prepu